BioSig Technologies, Inc. STEX Debt Instrument, Fair Value Disclosure

Debt Instrument, Fair Value Disclosure at other companies

Boston ScientificBSX

——

Revenue$13.0K+8.3%

Gross profit$12.0K-88.9%

Operating income-$35.7M-1,098%

Net income-$46.7M-1,560%

EPS (diluted)-$0.27-92.9%

Cash & equivalents$6.9M+84.0%

Total debt$15.0K-94.7%

Total equity$159.0M+6,003%

Total assets$173.3M+3,823%

Operating cash flow-$10.2M-813%

CapEx$4.0K-93.1%

Free cash flow-$2.9M+29.4%

Market cap$88.66M-61.8%

P/S2,216.6×-5,967×

Gross margin80.1%+25.2pp

Operating margin-32,155%-14,261pp

Net margin-25,825%-11,789pp

FCF margin-97,216.7%-106,293pp

Return on equity-627.1%—

Debt / equity0×—

Current ratio13.9×+11.5×

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentFairValue.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is BioSig Technologies, Inc.'s debt instrument, fair value disclosure?: BioSig Technologies, Inc. (STEX) reported debt instrument, fair value disclosure of $0 in Q1 2026.